Leptomeningeal metastases: A RANO proposal for response criteria

Marc Chamberlain, Larry Junck, Dieta Brandsma, Riccardo Soffietti, Roberta Rudà, Jeffrey Raizer, Willem Boogerd, Sophie Taillibert, Morris D. Groves, Emilie Le Rhun, Julie Walker, Martin Van Den Bent, Patrick Y. Wen, Kurt A. Jaeckle

Research output: Contribution to journalReview article

52 Citations (Scopus)

Abstract

Leptomeningeal metastases (LM) currently lack standardization with respect to response assessment. A Response Assessment in Neuro-Oncology (RANO) working group with expertise in LM developed a consensus proposal for evaluating patients treated for this disease. Three basic elements in assessing response in LM are proposed: a standardized neurological examination, cerebral spinal fluid (CSF) cytology or flow cytometry, and radiographic evaluation. The group recommends that all patients enrolling in clinical trials undergo CSF analysis (cytology in all cancers; flow cytometry in hematologic cancers), complete contrast-enhanced neuraxis MRI, and in instances of planned intra-CSF therapy, radioisotope CSF flow studies. In conjunction with the RANO Neurological Assessment working group, a standardized instrument was created for assessing the neurological exam in patients with LM. Considering that most lesions in LM are nonmeasurable and that assessment of neuroimaging in LM is subjective, neuroimaging is graded as stable, progressive, or improved using a novel radiological LM response scorecard. Radiographic disease progression in isolation (ie, negative CSF cytology/flow cytometry and stable neurological assessment) would be defined as LM disease progression. The RANO LM working group has proposed a method of response evaluation for patients with LM that will require further testing, validation, and likely refinement with use.

Original languageEnglish (US)
Pages (from-to)484-492
Number of pages9
JournalNeuro-Oncology
Volume19
Issue number4
DOIs
StatePublished - Apr 1 2017

Fingerprint

Neoplasm Metastasis
Cell Biology
Flow Cytometry
Neuroimaging
Disease Progression
Fluid Therapy
Neurologic Examination
Radioisotopes
Neoplasms
Clinical Trials

All Science Journal Classification (ASJC) codes

  • Oncology
  • Clinical Neurology
  • Cancer Research

Cite this

Chamberlain, M., Junck, L., Brandsma, D., Soffietti, R., Rudà, R., Raizer, J., ... Jaeckle, K. A. (2017). Leptomeningeal metastases: A RANO proposal for response criteria. Neuro-Oncology, 19(4), 484-492. https://doi.org/10.1093/neuonc/now183
Chamberlain, Marc ; Junck, Larry ; Brandsma, Dieta ; Soffietti, Riccardo ; Rudà, Roberta ; Raizer, Jeffrey ; Boogerd, Willem ; Taillibert, Sophie ; Groves, Morris D. ; Le Rhun, Emilie ; Walker, Julie ; Van Den Bent, Martin ; Wen, Patrick Y. ; Jaeckle, Kurt A. / Leptomeningeal metastases : A RANO proposal for response criteria. In: Neuro-Oncology. 2017 ; Vol. 19, No. 4. pp. 484-492.
@article{7f47618b3958469180b0c6a4aade446b,
title = "Leptomeningeal metastases: A RANO proposal for response criteria",
abstract = "Leptomeningeal metastases (LM) currently lack standardization with respect to response assessment. A Response Assessment in Neuro-Oncology (RANO) working group with expertise in LM developed a consensus proposal for evaluating patients treated for this disease. Three basic elements in assessing response in LM are proposed: a standardized neurological examination, cerebral spinal fluid (CSF) cytology or flow cytometry, and radiographic evaluation. The group recommends that all patients enrolling in clinical trials undergo CSF analysis (cytology in all cancers; flow cytometry in hematologic cancers), complete contrast-enhanced neuraxis MRI, and in instances of planned intra-CSF therapy, radioisotope CSF flow studies. In conjunction with the RANO Neurological Assessment working group, a standardized instrument was created for assessing the neurological exam in patients with LM. Considering that most lesions in LM are nonmeasurable and that assessment of neuroimaging in LM is subjective, neuroimaging is graded as stable, progressive, or improved using a novel radiological LM response scorecard. Radiographic disease progression in isolation (ie, negative CSF cytology/flow cytometry and stable neurological assessment) would be defined as LM disease progression. The RANO LM working group has proposed a method of response evaluation for patients with LM that will require further testing, validation, and likely refinement with use.",
author = "Marc Chamberlain and Larry Junck and Dieta Brandsma and Riccardo Soffietti and Roberta Rud{\`a} and Jeffrey Raizer and Willem Boogerd and Sophie Taillibert and Groves, {Morris D.} and {Le Rhun}, Emilie and Julie Walker and {Van Den Bent}, Martin and Wen, {Patrick Y.} and Jaeckle, {Kurt A.}",
year = "2017",
month = "4",
day = "1",
doi = "10.1093/neuonc/now183",
language = "English (US)",
volume = "19",
pages = "484--492",
journal = "Neuro-Oncology",
issn = "1522-8517",
publisher = "Oxford University Press",
number = "4",

}

Chamberlain, M, Junck, L, Brandsma, D, Soffietti, R, Rudà, R, Raizer, J, Boogerd, W, Taillibert, S, Groves, MD, Le Rhun, E, Walker, J, Van Den Bent, M, Wen, PY & Jaeckle, KA 2017, 'Leptomeningeal metastases: A RANO proposal for response criteria', Neuro-Oncology, vol. 19, no. 4, pp. 484-492. https://doi.org/10.1093/neuonc/now183

Leptomeningeal metastases : A RANO proposal for response criteria. / Chamberlain, Marc; Junck, Larry; Brandsma, Dieta; Soffietti, Riccardo; Rudà, Roberta; Raizer, Jeffrey; Boogerd, Willem; Taillibert, Sophie; Groves, Morris D.; Le Rhun, Emilie; Walker, Julie; Van Den Bent, Martin; Wen, Patrick Y.; Jaeckle, Kurt A.

In: Neuro-Oncology, Vol. 19, No. 4, 01.04.2017, p. 484-492.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Leptomeningeal metastases

T2 - A RANO proposal for response criteria

AU - Chamberlain, Marc

AU - Junck, Larry

AU - Brandsma, Dieta

AU - Soffietti, Riccardo

AU - Rudà, Roberta

AU - Raizer, Jeffrey

AU - Boogerd, Willem

AU - Taillibert, Sophie

AU - Groves, Morris D.

AU - Le Rhun, Emilie

AU - Walker, Julie

AU - Van Den Bent, Martin

AU - Wen, Patrick Y.

AU - Jaeckle, Kurt A.

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Leptomeningeal metastases (LM) currently lack standardization with respect to response assessment. A Response Assessment in Neuro-Oncology (RANO) working group with expertise in LM developed a consensus proposal for evaluating patients treated for this disease. Three basic elements in assessing response in LM are proposed: a standardized neurological examination, cerebral spinal fluid (CSF) cytology or flow cytometry, and radiographic evaluation. The group recommends that all patients enrolling in clinical trials undergo CSF analysis (cytology in all cancers; flow cytometry in hematologic cancers), complete contrast-enhanced neuraxis MRI, and in instances of planned intra-CSF therapy, radioisotope CSF flow studies. In conjunction with the RANO Neurological Assessment working group, a standardized instrument was created for assessing the neurological exam in patients with LM. Considering that most lesions in LM are nonmeasurable and that assessment of neuroimaging in LM is subjective, neuroimaging is graded as stable, progressive, or improved using a novel radiological LM response scorecard. Radiographic disease progression in isolation (ie, negative CSF cytology/flow cytometry and stable neurological assessment) would be defined as LM disease progression. The RANO LM working group has proposed a method of response evaluation for patients with LM that will require further testing, validation, and likely refinement with use.

AB - Leptomeningeal metastases (LM) currently lack standardization with respect to response assessment. A Response Assessment in Neuro-Oncology (RANO) working group with expertise in LM developed a consensus proposal for evaluating patients treated for this disease. Three basic elements in assessing response in LM are proposed: a standardized neurological examination, cerebral spinal fluid (CSF) cytology or flow cytometry, and radiographic evaluation. The group recommends that all patients enrolling in clinical trials undergo CSF analysis (cytology in all cancers; flow cytometry in hematologic cancers), complete contrast-enhanced neuraxis MRI, and in instances of planned intra-CSF therapy, radioisotope CSF flow studies. In conjunction with the RANO Neurological Assessment working group, a standardized instrument was created for assessing the neurological exam in patients with LM. Considering that most lesions in LM are nonmeasurable and that assessment of neuroimaging in LM is subjective, neuroimaging is graded as stable, progressive, or improved using a novel radiological LM response scorecard. Radiographic disease progression in isolation (ie, negative CSF cytology/flow cytometry and stable neurological assessment) would be defined as LM disease progression. The RANO LM working group has proposed a method of response evaluation for patients with LM that will require further testing, validation, and likely refinement with use.

UR - http://www.scopus.com/inward/record.url?scp=85019493398&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019493398&partnerID=8YFLogxK

U2 - 10.1093/neuonc/now183

DO - 10.1093/neuonc/now183

M3 - Review article

C2 - 28039364

AN - SCOPUS:85019493398

VL - 19

SP - 484

EP - 492

JO - Neuro-Oncology

JF - Neuro-Oncology

SN - 1522-8517

IS - 4

ER -

Chamberlain M, Junck L, Brandsma D, Soffietti R, Rudà R, Raizer J et al. Leptomeningeal metastases: A RANO proposal for response criteria. Neuro-Oncology. 2017 Apr 1;19(4):484-492. https://doi.org/10.1093/neuonc/now183